Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma — Stella

Recruiting

Back to Multiple Myeloma trials

Trial locations(1 site)

United Kingdom

The Royal Wolverhampton NHS Trust, Wolverhampton

Key details

Sponsor

The Royal Wolverhampton Hospitals NHS Trust

Collaborators

University of Wolverhampton

Enrollment target

~70 participants

Started

October 2021

Primary completion

December 2027

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov